This inventor holds 1 USPTO granted patent. Top assignee: Suzhou Smartnuclide Biopharmaceutical Co., Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Fangfang Li - Innovator in Biomedicine
Introduction
Fangfang Li is a notable inventor based in Suzhou, China. He has made significant contributions to the field of biomedicine, particularly in the development of polypeptides that bind to PD-L1. His work is crucial in the detection and diagnosis of PD-L1 related diseases, including various forms of cancer.
Latest Patents
Fangfang Li holds 1 patent for his invention titled "PD-L1-binding polypeptide and use thereof." This invention focuses on the application of PD-L1 binding polypeptides in the medical field, specifically for diagnosing and detecting diseases associated with PD-L1.
Career Highlights
Fangfang Li is currently employed at Suzhou Smartnuclide Biopharmaceutical Co., Ltd. His role in the company allows him to further his research and development efforts in biomedicine. His innovative approach has positioned him as a key figure in the advancement of cancer diagnostics.
Collaborations
Fangfang Li collaborates with talented individuals in his field, including his coworkers Tao Xu and Yan Sun. Their combined expertise enhances the research and development initiatives at their company.
Conclusion
Fangfang Li's contributions to biomedicine through his innovative patent demonstrate his commitment to advancing cancer diagnostics. His work is vital in the ongoing fight against PD-L1 related diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile